Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
Enveric Biosciences (NASDAQ:ENVB), a biotechnology company specializing in neuroplastogenic small-molecule therapeutics, revealed positive data from preclinical safety and pharmacology studies of its lead drug candidate, EB-003. The Massachusetts-based company announced that the results show the drug’s ability to selectively target serotonergic receptors, offering potential benefits for mental health conditions such as depression, anxiety and addiction without inducing hallucinations.
What Happened: The in vitro studies demonstrated EB-003’s selective activity on serotonergic neuroreceptors while confirming its minimal off-target interactions. These findings reduce concerns about the adverse cardiovascular and central nervous …